Global Sexually Transmitted Disease Testing Market Definition
Infections transmitted from one individual to another throughout numerous kinds of sexual activity are referred to as sexually transmitted diseases. There are over 20 multiple types of sexually transmitted diseases, including genital herpes, chlamydia, HIV, gonorrhea, human papillomavirus, syphilis, trichomoniasis, and others. Antibiotics are frequently employed to treat sexually transmitted diseases triggered by bacteria, yeast, or parasites. Every day, over one million new reports of sexually transmitted illnesses are reported worldwide, based on the World Health Organization. If the adult has an existing sexually transmitted disease (STD), the person is more likely to be infected with the human immunodeficiency virus (HIV).
Sexually transmitted diseases are ailments spread through sexual contact. Moreover, this contact is typically vaginal, verbal, or anal. However, they can often be dispersed through all the other intimate physical interactions such as herpes and HPV, that are spread through epidermis contact. Bacteria, pathogens, or parasites are to be held responsible for these diseases. In certain cases, sexually transmitted diseases might also be transferred via breastfeeding, birth, and common needle use.
Moreover, testing is recommended usually for the detection of any kind of diseases, therefore, young people under the age of 25 must have a yearly screening. Test and evaluations aid in the detection and treatment of STDs. Certain STDs, if left untreated, can lead to severe and long-term health issues such as vision loss, neurological disorders, reduced fertility, deformities, and even death. Fortunately, all STDs can be treated, and several can even be completely cured.
Global Sexually Transmitted Disease Testing Market: Key Insights
|
Base Year |
2022 |
|
Forecast Year |
2023-2033 |
|
CAGR |
~6% |
|
Base Year Market Size (2022) |
~ USD 95 Billion |
|
Forecast Year Market Size (2033) |
~ USD 145 Billion |
|
Regional Scope |
|
Global Sexually Transmitted Disease Testing Market Size, Forecast, and Trend Highlights Over 2023 - 2033
The global sexually transmitted disease testing market is estimated to garner a revenue of ~USD 145 billion by the end of 2033 by growing at a CAGR of ~6% over the forecast period, i.e., 2023 – 2033. Further, the market generated a revenue of ~USD 95 billion in the year 2022. An increase in cases of sexually transmitted diseases (STDs) in the younger adult population, followed by unprotected sex and a lower level of awareness about safe sex in younger adults, are expected to increase the transmission of diseases. Hence, it is anticipated to boost the growth of the global sexually transmitted disease testing market. As per the data reported, every 1 in 4 teens gets infected by STD every year around the globe.
Get more information on this report:Download Sample PDF
The rise in sexual crimes against women has accelerated the transmission of sexually transmitted infections among women. Rape, sexual molestation, and assault against women are expected to increase sexually transmitted diseases, which are projected to bring lucrative growth opportunities. According to the United Nations, globally, 736 million women, at least once in their lifetime have experienced sexual intimate partner violence, non-partner violence, or both. Furthermore, a higher number of people working as sex workers, insurance covering the treatment of STDs, and increased cases of STDs are propelling the growth of the global sexually transmitted disease testing market. Moreover, HIV remains a significant public health concern around the world. Therefore, the goal of testing is to identify individuals that are suffering from the STD, so that it cannot be transferred to a healthy person. In the United Kingdom, for instance, the National Chlamydia Screening Program (NCSP) was launched in March 2022. The project's primary objective is to decrease the threat of undiagnosed chlamydia infection.
Global Sexually Transmitted Disease Testing Market: Growth Drivers and Challenges
Growth Drivers
-
Insurance Policy for STD Testing and Treatment - In many cases, health insurance companies offer urgent care STD testing. As a result, patients with limited financial resources are expected to benefit from these policies, which are estimated to contribute to market growth. For instance, the Affordable Care Act (ACA) requires that most private insurance plans and public health coverage projects, such as Medicaid, encompass STI screening and counseling at no cost.
-
Rise in Global Population of Young Adults - Young adults are generally more curious, both sexually and socially active. As a result, their broadened mentality leads them to engage sexually with more partners, therefore, they are more susceptible to STDs. This trend is expected to fuel the market’s growth over the forecast period. By the statistics of the WHO, globally one in 20 young people catches STD each year. The rate is higher among the age group of 20-24 years.
-
Alarming Elevation in the Number of Rape Cases and Sexual Harassment - According to the WHO, every 1 in 3 women experience sexual violence at least once in their lifetime worldwide.
-
Rising Prevalence of Sexually Transmitted Disease (STD) - Cases of sexually transmitted is rising owing to people's active sexual life, choices of multiple partners and not using contraceptives. According to a World Health Organization report released in November 2021, over 1.0 million sexually transmitted infections are obtained globally, with the majority of them being asymptomatic. It also stated that approximately 374.0 million new infections with one of four sexually transmitted infections occurring annually: gonorrhea, chlamydia, trichomoniasis, and syphilis. As a consequence of the growing frequency and prevalence rate of sexually transmitted diseases around the world, the requirement for STD diagnostics is anticipated to rise, expanding market growth during the forecast period.
Challenges
- Social Stigma Sticked with Sexually Transmitted Diseases - There is a huge share of the population, that hesitates to talk about sex or go for STD testing and treatment. Sexually transmitted disease is proven to be a common disease, despite the social stigma surrounding STDs, still exists. Even after the rise in the educated population, people have a false notion about sex or sex-related problems. Therefore, the rising social stigma is expected to hinder market growth.
- Higher Cost of Systems Required for STD Detection
- Inaccurate Result by Detection Systems
The global sexually transmitted disease testing market is segmented and analyzed for demand and supply by disease into human immunodeficiency virus, herpes simplex virus, human papillomavirus, chlamydia, syphilis, gonorrhea, cancroid, and others. Out of these, the chlamydia segment is expected to garner the highest revenue by the end of 2033. This can be attributed to the higher instances of chlamydia in the younger population owing to unprotected sex and in adults owing to involvement with different partners. Furthermore, there has been surging awareness related to chlamydia treatment, that is further predicted to boost the segment’s growth in the market. According to the World Health Organization, in 2020 there was nearly 129 million instances of chlamydia around the world. The Center for Disease Control and Prevention reported a total of 1,808,703 cases of chlamydia in 2019.
The market is segmented by location into laboratory and point of care. Out of these, the laboratory segment is expected to garner highest revenue, as laboratories are the most commonly used place for assessing Sexually Transmitted Diseases (STDs) worldwide. The blood screening is performed in laboratories with proper care in order to give correct results, and it is predicted to surge the segment’s growth in the market. Moreover, laboratory tests are precise and trustworthy, their use is widespread, and people place more faith in them, that is further anticipated to surge the segment’s growth in the market. Abbott laboratories provide an in vitro reverse transcription-polymerase chain reaction (RT-PCR) test and an in vitro polymerase chain reaction (PCR) assay for the identification of sexually transmitted diseases induced by Chlamydia trachomatis, Trichomonas vaginalis, and Mycoplasma genitalium, including gonorrhea. Correspondingly, Qiagen Inc. offers a diverse selection of screening test kits, along with STI assessments for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infections with significant clinical sensitiveness and specificity, that are utilized to identify a variety of sexually transmitted diseases. More product introductions enable laboratories to configure devices or machinery as needed. For instance, with European Commission authorization, Qiagen Inc. released the NeuMoDxHSV 1/2 Quant Test for the measurement and distinction of herpes simplex virus type 1 (HSV-1) DNA and/or herpes simplex virus type 2 (HSV-2) in May 2022. These factors, as a result, are anticipated to create numerous opportunities for the growth of the segment in the coming years.
Global Sexually Transmitted Disease Testing Market Regional Synopsis
The Asia Pacific sexually transmitted disease testing market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2033. This can be attributed to the rising crimes related to sexual harassment in the region are increasing the chances of sexually transmitted disease along with the rising population, and the lack of sex education. In 2021, nearly 86 daily rapes and around 50 sexual crimes against women have been reported every hour in India. Moreover, in Thailand, the population of sex workers is around 250,000 to 2 million. Additionally, in 2021, over 20,000 deaths were caused by STDs in China, and nearly 20 thousand people died of AIDS.
On the other hand, the North America region is also expected to have a fastest growth owing to the increased incidence of STDs in the region. Moreover, there has been rising number of a substantial of clinical organizations and increased disease consciousness, that is anticipated to drive the market’s growth in the North American region. A survey released in April 2022 by the Centers for Disease Control and Prevention (CDC) titled "Sexually Transmitted Disease Surveillance, 2020" asserted that STDs persist as a major public health issue in the nation. Based on the same source, Chlamydia trachomatis disease was the highest common reportable sexually transmitted infection in the United States in 2020, with 1,579,885 people infected as per the CDC.
Market Segmentation
Our in-depth analysis of the global sexually transmitted disease testing market includes the following segments:
|
By Disease |
|
|
By Location |
|
|
By Device |
|
Top Featured Companies Dominating the Global Sexually Transmitted Disease Testing Market
·Abbott Laboratories
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- bioMerieux
- Becton Dickinson and Company
- Quest Diagnostics
- Thermo Fisher Scientific
- Hologic Inc.
- Orasure Technologies, Inc.
- S&P Global
- DiaSorin Molecular LLC.
